Antigen News and Research

RSS

Optimization of CAR T cells to destroy solid tumors

A team led by LMU physician Sebastian Kobold has found a way to allow the body's immune system to destroy solid tumors.

16 Feb 2026

HER2 gastric cancer: Unraveling resistance at single-cell resolution

HER2-positive gastric cancer accounts for a substantial proportion of advanced cases and has long been treated with HER2-targeted therapies.

16 Feb 2026

Engineered Listeria boosts innate immunity against cancer

After nearly 40 years of research on how Listeria bacteria manipulate our cells and battle our immune system to cause listeriosis, Daniel Portnoy and his colleagues have discovered a way to turn the bacteria into a potent booster of the immune system - and a potential weapon against cancer.

13 Feb 2026

New AI framework enables reliable intracellular antibody design

A new artificial intelligence-driven pipeline developed in a collaborative research combines protein structure prediction, sequence design, and live-cell screening together to enable rapid conversion of antibody sequences into functional intracellular antibodies (intrabodies) that are stable within living cells.

13 Feb 2026

Human insight and AI advance prostate cancer treatment

Today, many men must choose between life-altering prostate removal or careful long-term monitoring. The EU-funded ROBIOSPY Project offers an intermediate option: precise needle-based diagnostics and targeted therapy powered by AI-driven robotics.

12 Feb 2026

Nanovaccine design boosts immune attack on HPV tumors

Throughout the past decade, Northwestern University scientists have uncovered a striking principle of vaccine design: Performance depends not only on vaccine components but also on vaccine structure.

11 Feb 2026

Trial highlights promising frontline therapy for blastic plasmacytoid dendritic cell neoplasm

Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) had a complete response, according to new data from the Phase I/II multicenter international CADENZA trial led by researchers at The University of Texas MD Anderson Cancer Center.

11 Feb 2026

Study uncovers immune trigger behind vaccine-induced immune thrombocytopenia and thrombosis

A global research collaboration of scientists from McMaster University (Canada), Flinders University (Australia) and Universitätsmedizin Greifswald (Germany) uncovered why a small number of people developed dangerous blood clots after either receiving certain COVID‑19 vaccines or experiencing a natural adenovirus infection, and the answer lies in an unexpected case of misdirected targeting by the immune system.

11 Feb 2026

Alzheimer’s plaques decline after CAR-T immune cell treatment in preclinical study

Researchers engineered CD4+ chimeric antigen receptor T cells targeting fibrillar amyloid beta and tested them in a mouse Alzheimer model. The preclinical study showed reduced amyloid pathology and altered neuroimmune responses, supporting CAR-T immunotherapy as a potential future Alzheimer strategy.

11 Feb 2026

New strategy harnesses pre-existing antiviral immunity to boost anti-tumor responses

Because many different types of cancer cells overexpress programmed death-ligand 1 (PD-L1), this cell surface protein is a major target of cancer immunotherapy.

11 Feb 2026

Engineered CAR-T cells reduce Alzheimer’s plaques in mice

Chimeric antigen receptor (CAR) T cell therapy, a type of immunotherapy that leverages the immune system to combat diseases, is a powerful treatment option for certain cancers.

9 Feb 2026

PSMA PET/CT scans may predict prostate cancer recurrence, guide treatment

New research in the February 2026 issue of JNCCN-Journal of the National Comprehensive Cancer Network found that incorporating information from prostate-specific membrane antigen (PSMA) PET/CT scans may be able to predict progression-free survival (PFS) and guide treatment planning in patients with rising prostate-specific antigen (PSA) levels following removal of the prostate.

9 Feb 2026

New DNA-based vaccine scaffolds boost targeted immune responses to HIV

One of the biggest hurdles in developing an HIV vaccine is coaxing the body to produce the right kind of immune cells and antibodies. In most vaccines, HIV proteins are attached to a larger protein scaffolding that mimics a virus.

6 Feb 2026

Gut microbial butyrate enhances mucosal vaccine antibody responses

A research team from POSTECH and ImmunoBiome in Korea, led by Professor Sin-Hyeog Im, has uncovered a new mechanism showing how butyrate-a short-chain fatty acid produced by gut commensal bacteria-enhances T follicular helper (Tfh) cell activity to promote antibody production and strengthen mucosal vaccine efficacy.

4 Feb 2026

Engineered yeast cells accelerate testing of cancer immunotherapies

Engineered yeast cells can mimic real cancer cells and be used to test new cancer immunotherapies much faster, benefiting patients.

4 Feb 2026

New liquid biopsy detects early cancers through epigenetic instability

Researchers at the Johns Hopkins Kimmel Cancer Center have developed a novel liquid biopsy approach to identify early-stage cancers by measuring the random variation in DNA methylation patterns, rather than the absolute level of those patterns as in other liquid biopsies.

2 Feb 2026

How the CDC prepares influenza vaccines for pandemics

CDC scientists outline the comprehensive methodology involved in the development of influenza candidate vaccine viruses.

2 Feb 2026

Nasal spray vaccine prevents infection from highly pathogenic H5N1 virus

Researchers at WashU Medicine have developed a nasal vaccine against the highly pathogenic H5N1 avian influenza virus, or bird flu, which has jumped from wild birds to livestock to humans.

30 Jan 2026

Dynamic viral markers predict treatment response in hepatitis B

The rate of functional cure (HBsAg loss) remains unsatisfactory following pegylated interferon (PEG-IFN) treatment in chronic hepatitis B. To optimize PEG-IFN administration, this study aimed to evaluate virological markers to predict functional cure and/or hepatitis B e antigen (HBeAg) loss.

30 Jan 2026

Researchers develop blood test to find pancreatic ductal adenocarcinoma

National Institutes of Health (NIH)-supported investigators have developed a blood test to find pancreatic ductal adenocarcinoma, one of the deadliest forms of cancer.

30 Jan 2026